Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...
Verywell Health on MSN
How complement 3 glomerulopathy is diagnosed: Step-by-step
Medically reviewed by Jamin Brahmbhatt, MD Key Takeaways Complement 3 glomerulopathy (C3G) is diagnosed with a combination of ...
Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 ...
Health on MSN
How rare is complement 3 glomerulopathy?
Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms ...
Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...
Advancing investigational pre-clinical research of APL-9099 3, a potential one-time neonatal Fc receptor (FcRn) treatment ...
On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...
Verywell Health on MSN
Proteinuria in Complement 3 Glomerulopathy: Why It Matters and What to Do
Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.
Bringing together traditional Chinese medicine and contemporary medicine could improve outcomes for patients with chronic disease. In this Q&A, Lidian Chen, professor and chief physician at Fujian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback